The United Kingdom moves ahead with a closely watched clinical trial of puberty-blocking drugs after agreeing new minimum age rules for participants. BBC Health and BBC News report that children who are gender-questioning must be at least 11 years old to take part in the trial. Jowhar.com similarly says the study has been allowed to continue under the updated age requirements, noting that the project had been paused in February following intervention by the Medicines regulator.
The reporting also reflects continuing debate around the trial. Jowhar.com and RTE News (Ireland) describe mounting pressure from critics who argue the study should be scrapped altogether, citing concerns about potential harm to young people. At the same time, the trial’s continuation with defined eligibility criteria indicates regulators proceed while addressing specific concerns through trial rules.
Taken together, the sources describe a trial that is resuming with an age threshold set at 11, following a earlier pause, amid an ongoing public dispute over whether such medicines should be studied and, if so, for which age group.
